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ATOT = total concentration of weak acid; CO2TOT = total concentration of CO2; PaCO2 = arterial CO2 tension; PCO2 = partial CO2 tension; SBE =
standard base excess; SID = strong ion difference.
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Abstract
Stewart’s quantitative physical chemical approach enables us to
understand the acid–base properties of intravenous fluids. In
Stewart’s analysis, the three independent acid–base variables are
partial CO2 tension, the total concentration of nonvolatile weak
acid (ATOT), and the strong ion difference (SID). Raising and
lowering ATOT while holding SID constant cause metabolic
acidosis and alkalosis, respectively. Lowering and raising plasma
SID while clamping ATOT cause metabolic acidosis and alkalosis,
respectively. Fluid infusion causes acid–base effects by forcing
extracellular SID and ATOT toward the SID and ATOT of the
administered fluid. Thus, fluids with vastly differing pH can have the
same acid–base effects. The stimulus is strongest when large
volumes are administered, as in correction of hypovolaemia, acute
normovolaemic haemodilution, and cardiopulmonary bypass. Zero
SID crystalloids such as saline cause a ‘dilutional’ acidosis by
lowering extracellular SID enough to overwhelm the metabolic
alkalosis of ATOT dilution. A balanced crystalloid must reduce
extracellular SID at a rate that precisely counteracts the ATOT
dilutional alkalosis. Experimentally, the crystalloid SID required is
24 mEq/l. When organic anions such as L-lactate are added to
fluids they can be regarded as weak ions that do not contribute to
fluid SID, provided they are metabolized on infusion. With colloids
the presence of ATOT is an additional consideration. Albumin and
gelatin preparations contain ATOT, whereas starch preparations do
not. Hextend is a hetastarch preparation balanced with L-lactate. It
reduces or eliminates infusion related metabolic acidosis, may
improve gastric mucosal blood flow, and increases survival in
experimental endotoxaemia. Stored whole blood has a very high
effective SID because of the added preservative. Large volume
transfusion thus causes metabolic alkalosis after metabolism of
contained citrate, a tendency that is reduced but not eliminated
with packed red cells. Thus, Stewart’s approach not only explains
fluid induced acid–base phenomena but also provides a framework
for the design of fluids for specific acid–base effects.
Introduction
There is a persistent misconception among critical care
personnel that the systemic acid–base properties of a fluid
are dictated by its pH. Some even advocate ‘pH-balanced’
fluids, particularly when priming cardiopulmonary bypass
pumps [1]. This is not to deny the merit of avoiding very high
or very low pH in fluids intended for rapid administration.
Extremes of pH can cause thrombophlebitis, and on
extravasation tissue necrosis, and rapid administration is a
hemolysis risk (specific data on this topic are sparse).
However, these effects occur before equilibration. What must
be understood is that fluids with widely disparate pH values
can have exactly the same systemic acid–base effects. To
illustrate, the acid–base properties of ‘pure’ 0.9% saline
(pH 7.0 at 25°C) are identical to those of 0.9% saline
equilibrated with atmospheric CO2 (pH 5.6 at 25°C).
Until recently, the challenge was to find a logical basis for
predicting the acid–base properties of intravenous fluids. In this
review important concepts of quantitative physical chemistry
are presented, concepts originally set out by the late Peter
Stewart [2–5]. They provide the key to understanding fluid
induced acid–base phenomena and allow a more informed
approach to fluid design. On this background we consider the
effects of intravenous fluids on acid–base balance.
The Stewart approach in brief
There are just three independent variables that, when
imposed on the physical chemical milieu of body fluids,
dictate their acid–base status. They are strong ion difference
(SID), the total weak acid concentration (ATOT), and partial
CO2 tension (PCO2). The interplay between SID, ATOT, and
PCO2 is the sole determinant of pH, as well as of other
dependent variables such as [HCO3
–]. All acid–base
interventions, including fluid administration, act through SID,
ATOT and PCO2, alone or in combination. The single
exception is the addition of weak base (e.g. tris-hydroxymethyl
aminomethane) [6], which is normally absent from body fluids.
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Strong ion difference
Elements such as Na+, K+, Ca2+, Mg2+, and Cl– exist in body
fluids as completely ionized entities. At physiologic pH this can
also be said of anions with pKa values of 4 or less, for example
sulphate, lactate, and β-hydroxybutyrate. Stewart described all
such compounds as ‘strong ions’. In body fluids there is a
surfeit of strong cations, quantified by SID. In other words, SID
= [strong cations] – [strong anions]. Being a ‘charge’ space,
SID is expressed in mEq/l. SID calculated from measured
strong ion concentrations in normal plasma is 42 mEq/l.
Partial CO2 tension
Arterial PCO2 (PaCO2) is an equilibrium value determined by
the balance between CO2 production (15,000 mmol/day) and
CO2 elimination via the lungs. In areas where PCO2 is less
directly controlled by alveolar ventilation (e.g. venous blood
and interstitial fluid during low flow states), the total CO2
concentration (CO2TOT) becomes the independent variable.
Total concentration of weak acid (ATOT)
Body fluid compartments have varying concentrations of
nonvolatile (i.e. non-CO2) weak acids. In plasma these
consist of albumin and inorganic phosphate. The same
applies to interstitial fluid, although total concentrations here
are very small. In red cells the predominant source is
haemoglobin.
Nonvolatile weak acids dissociate in body fluids as follows:
HA ↔ H+ + A–
The group of ions summarized as A– are weak anions (pKa
approximately 6.8). Unlike strong ions, weak ions in body fluids
vary their concentrations with pH by dissociation/association
of their respective parent molecules. The total concentration of
nonvolatile weak acid in any compartment is termed ATOT,
where ATOT = [HA] + [A–]. Although [A–] varies with pH, ATOT
does not, and as such it is an independent variable.
Weak ions
The SID space is filled by weak ions, one of which is A–. The
only other quantitatively important weak ion is HCO3
–, but
there are also minute concentrations of CO3
2–, OH–, and H+.
To preserve electrical neutrality, their net charge must always
equal the SID.
Stewart’s equations
Stewart set out six simultaneous equations primarily
describing the behaviour of weak ions occupying the SID
space (Table 1). They are applications of the Law of Mass
Action to the dissociation of water, H2CO3, HCO3
–, and
nonvolatile weak acids, coupled with the expression for ATOT
and a statement of electrical neutrality. If PCO2, SID and ATOT
are known, then the equations in Table 1 can be solved for
the remaining six unknowns – [A–], [HCO3
–], [OH–], [CO3
2–],
[HA] and, most importantly, [H+].
Isolated abnormalities in strong ion difference and total
concentration of weak acid (ATOT)
From Stewart’s equations, four simple rules can be derived
concerning isolated abnormalities in SID and ATOT (Table 2).
These can be verified by in vitro experimentation [7].
Standard base excess
The rules in Table 2 illustrate an important Stewart principle.
Metabolic acid–base disturbances arise from abnormalities in
SID and ATOT, either or both. However, to quantify metabolic
acid–base status at the bedside, neither SID nor ATOT needs
individual measurement. For this the standard base excess
(SBE) is sufficient. The SBE concept was developed by
Siggaard-Andersen and the Copenhagen group [8,9]. It is
calculated from buffer base offsets by assuming a mean
extracellular haemoglobin concentration of 50 g/l. A useful
formula is as follows (with SBE and [HCO3
–] values
expressed in mEq/l):
SBE = 0.93 × {[HCO3
–] + 14.84 × (pH – 7.4) – 24.4}
SBE supplements the Stewart approach as a practical tool
[10–12]. A typical reference range is –3.0 to +3.0 mEq/l. The
SBE deviation from zero is the change in extracellular SID
needed to normalize metabolic acid–base status without
changing ATOT. If the SBE is below –3.0 mEq/l then there is
metabolic acidosis, either primary or compensatory. The
deviation below zero is the increase in extracellular SID
needed to correct the acidosis. Although this value should
also equate to the dose (in mmol) of NaHCO3 required per
litre of extracellular fluid, in practice more is usually needed –
a dose corresponding to an extracellular space of 30% body
weight rather than 20%. Similarly, if the SBE is greater than
3.0 mEq/l then there is metabolic alkalosis. The positive offset
from zero represents a theoretical dose calculation for HCl
rather than for NaHCO3.
Thinking about fluids in Stewart’s terms
Fluids are administered into the physiological milieu. Their in
vivo properties can therefore be described using Stewart’s
physical chemical language, in other words in terms of their
SID, ATOT and CO2TOT [13]. Acid–base effects come about
Table 1
Stewart’s six simultaneous equations
[H+] × [OH–] = K’w
[H+] × [A–] = Ka × HA
[HA] + [A–] = ATOT
[H+] × [HCO3
–] = Kc × PCO2
[H+] × [CO3
2–] = Kd × [HCO3
–]
SID + [H+] – [HCO3
–] – [CO3
2–] – [A–] – [OH–] = 0
All K values are known dissociation constants. PCO2, partial CO2
tension; SID, strong ion difference.206
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as a fluid with a particular set of physical chemical properties
mixes and equilibrates with extracellular fluid (which itself
continually equilibrates across cell membranes with
intracellular fluid). This alters extracellular SID and ATOT, the
final determinants of metabolic acid–base status, toward the
SID and ATOT of the infused fluid.
The CO2TOT of infused fluid is worth mentioning separately.
First, it has no effect on extracellular SID and ATOT, and
therefore it does not influence the final metabolic acid–base
status. In other words, it is not the presence of HCO3
– in
bicarbonate preparations that reverses a metabolic acidosis;
rather, it is the high SID (1000 mEq/l for 1 mol/l NaHCO3
–)
and the absence of ATOT. The same metabolic effect would
be achieved if the weak anion were OH– rather than HCO3
–,
although the resultant high pH (14.0 rather than 7.7)
introduces a risk for haemolysis and tissue damage, and
mandates extremely slow administration via a central vein.
However, the CO2TOT of administered fluid can be important
for other reasons. Rapid infusion of fluids with high CO2TOT
can transiently alter CO2 homeostasis, mainly in areas under
less direct control of respiratory servo loops, such as venous
blood, the tissues and the intracellular environment [14–18].
The crystalloid and colloid fluids discussed in this review are
not in this category.
Crystalloid effects from the Stewart perspective
No crystalloid contains ATOT. Crystalloid loading therefore
dilutes plasma ATOT, causing a metabolic alkalosis (Table 2).
Simultaneously, plasma and extracellular SID are forced
toward the SID of the infused crystalloid, primarily by
differential alteration in [Na+] and [Cl–]. If these changes
increase SID then the effects of ATOT dilution are enhanced,
and if they decrease SID then they oppose them (Table 2).
‘Dilutional’ acidosis
It has been reported on many occasions that large-scale
saline infusions can cause a metabolic acidosis [19–21].
Although best documented during repletion of extracellular
fluid deficits, acute normovolaemic haemodilution [22,23] and
cardiopulmonary bypass [23–26] have similar potential. The
mechanism is not bicarbonate dilution, as is commonly
supposed [27]. Bicarbonate is a dependent variable. The key
fact is that the SID of saline is zero, simply because the
strong cation concentration ([Na+]) is exactly the same as the
strong anion concentration ([Cl–]). Large volumes of saline
therefore reduce plasma and extracellular SID. This easily
overwhelms the concurrent ATOT dilutional alkalosis. A normal
(in fact reduced) anion gap metabolic acidosis is the end
result [28,29], albeit less severe than if ATOT had remained
constant.
The critical care practitioner should be alert to this possibility
when confronted with a patient who has a metabolic acidosis
and a normal anion gap. It is wise to check that the corrected
anion gap [30,31] and perhaps the strong ion gap [32,33]
are also normal. These are thought to be more reliable
screening tools for unmeasured anions [34,35]. (For a more
detailed discussion of the anion gap, corrected anion gap
and strong ion gap, see other reviews in this issue.) A history
of recent large volume saline infusion (e.g. >2 l in <24 hours)
in such a patient is highly suggestive of infusion related
metabolic acidosis. Even if there is an alternative explanation,
such as renal tubular acidosis or enteric fluid loss, saline
infusions will perpetuate and exacerbate the problem.
The phenomenon is not confined to 0.9% saline, and the
resultant metabolic acidosis may or may not be hyper-
chloraemic. Hypotonic NaCl solutions also have a zero SID.
Even fluids with no strong ions at all, such as dextrose
solutions, mannitol and water, have a zero SID. Infusion of any
of these fluids reduces plasma and extracellular SID by the
same equilibration mechanism, irrespective of whether
plasma [Cl–] rises or falls, forcing acid–base in the direction
of metabolic acidosis [36]. For a theoretical illustration of
dilutional SID effects, imagine adding 1 l of either saline or
water to a sealed 3 l mock ‘extracellular’ compartment with a
SID of 40 mEq/l, as illustrated in Table 3. In either case the
SID is reduced to 30 mEq/l, but with a fall in [Cl–] after water
dilution.
Interestingly, hypertonicity makes solutions more acidifying
[36]. In this case the reduction in extracellular SID is
magnified by an added dilution effect, because water is
drawn by osmosis from the intracellular space. An unproven
corollary is that hypotonic solutions are less acidifying. The
important message here is that the intracellular space is a
participant in the final equilibrium, and can contribute
significantly to fluid induced acid–base effects.
‘Saline responsive’ metabolic alkalosis
Patients categorized as suffering from ‘contraction alkalosis’
or ‘diminished functional extracellular fluid volume’ are said to
be ‘saline responsive’, and complex hormonal and renal
tubular mechanisms are often invoked [37–39]. In fact, from
the perspective of physical chemistry, any metabolic alkalosis
is ‘saline responsive’, provided sufficient saline (or any zero
SID fluid) can be administered. Unfortunately, in the absence
Table 2
Rules for isolated abnormalities in strong ion difference (SID)
and total concentration of weak acid (ATOT)
SID/ATOT Isolated abnormality Result
SID Increased Metabolic alkalosis
SID Decreased Metabolic acidosis
ATOT Increased Metabolic acidosis
ATOT Decreased Metabolic alkalosis207
of hypovolaemia the amount of saline required introduces a
risk for overload.
Hence, a diagnosis of volume depletion should be established
before treating metabolic alkalosis in this way. Signs of
extracellular volume depletion include reduced skin turgor,
postural hypotension, and systolic pressure variability [40].
There may also be a prerenal plasma biochemical pattern
(high urea:creatinine ratio), and if tubular function is preserved
then urinary [Na–] is normally under 20 mmol/l [41].
KCl and metabolic alkalosis
Some types of metabolic alkalosis are associated with
hypokalaemia and total body potassium deficits [37,42].
When dealing with these categories, correcting the deficit
with KCl is a particularly effective way to reverse the alkalosis.
From the Stewart perspective, this practice has similarities to
infusing HCl, minus the pH disadvantages of a negative SID.
This is because potassium and potassium deficits are
predominantly intracellular, and so all but a small fraction of
retained potassium ends up within the cells during correction.
The net effect of KCl administration is that the retained strong
anion (Cl–) stays extracellullar, whereas most of the retained
strong cation disappears into the intracellular space. This is a
potent stimulus for reducing plasma and extracellular SID.
To give another rough illustration, imagine the repletion of a
200 mmol total body potassium deficit using KCl. If the
extracellular [K+] is increased by 3 mmol/l during the process,
then approximately 50 mmol of K+ has been retained in the
17 l extracellular space and about 150 mmol has crossed into
the cells. This means that 150 mmol Cl– is left behind in the
extracellular space, now unaccompanied by a strong cation.
This lowers extracellular SID and thus SBE by about 9 mEq/l.
‘Balanced’ crystalloids
To avoid crystalloid induced acid–base disturbances, plasma
SID must fall just enough during rapid infusion to counteract
the progressive ATOT dilutional alkalosis. Balanced
crystalloids thus must have a SID lower than plasma SID but
higher than zero. Experimentally, this value is 24 mEq/l
[23,43]. In other words, saline can be ‘balanced’ by replacing
24 mEq/l of Cl– with OH–, HCO3
– or CO3
2–. From this
perspective, and for now ignoring pH, solutions 1 and 3 in
Table 4 are ‘balanced’. However, it is noteworthy that, unless
stored in glass, solutions 1 and 3 both become solution 2 by
gradual equilibration with atmospheric CO2 (Table 4).
Solution 2 is also ‘balanced’.
To eliminate the issue of atmospheric equilibration,
commercial suppliers have substituted various organic anions
such as L-lactate, acetate, gluconate and citrate as weak ion
surrogates. Solution 4 (Table 4) is a generic example of this
approach (for actual examples, see Table 5). L-lactate is a
strong anion, and the in vitro SID of solution 4 is zero.
However, solution 4 can also be regarded as ‘balanced’,
provided L-lactate is metabolized rapidly after infusion. In fact,
in the absence of severe liver dysfunction, L-lactate can be
metabolized at rates of 100 mmol/hour or more [44,45],
which is equivalent to nearly 4 l/hour of solution 4. The in vivo
or ‘effective’ SID of solution 4 can be calculated from the
L-lactate component subject to metabolic ‘disappearance’. If
the plasma [lactate] stays at 2 mmol/l during infusion, then
solution 4 has an effective SID of 24 mEq/l.
Hence, despite wide variation in pH, solutions 1–4 in Table 4
have identical effective SID values. They are all ‘balanced’,
with identical systemic acid–base effects. However, other
attributes must be considered. Solution 1 (pH 12.38) is too
alkaline for peripheral or rapid central administration. The
situation for solution 2 is less clear. Atmospheric equilibration
has brought the pH to 9.35, which is less than that of sodium
thiopentone (pH 10.4) [46] – a drug that is normally free of
venous irritation. Similarly Carbicarb, a low CO2TOT alternative
to NaHCO3 preparations [47], has a pH of 9.6 [48]. Thus, the
pH of solution 2 may not preclude peripheral or more rapid
central administration. On the downside, and like Carbicarb,
solution 2 contains significant concentrations of carbonate,
which precipitates if traces of Ca2+ or Mg2+ are present. A
chelating agent such as sodium edetate may be required.
Choosing a balanced resuscitation crystalloid
Hartmann’s solution (Table 5) is the best known commercial
‘balanced’ preparation. It contains 29 mmol/l of L-lactate. In
the absence of severe liver dysfunction, the effective SID is
therefore approximately 27 mEq/l. Although this should make
it slightly alkalinizing, much as Hartmann originally intended
[49], it is close to the ideal from an acid–base perspective.
Slight alkalinization is difficult to demonstrate in laboratory
and especially in clinical studies, but the available evidence
shows that Hartmann’s solution reduces or eliminates
infusion related metabolic acidosis [50–54].
The acid–base status of a patient before resuscitation is a
consideration. If it is normal to start with, then higher SID
fluids such as Plasma-Lyte 148 (effective SID 50 mEq/l;
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Table 3
Equivalent strong ion difference reductions by adding 1 l water
or 1 l of 0.15 mol/l NaCl to a 3 l sample of mock extracellular
fluid
After saline  After water 
‘ECF’ dilution dilution
[Na+] 140 142.5 105
[Cl–] 100 112.5 75
[A–] + [HCO3
–]4 0 3 0 3 0
SID 40 30 30
Electrolyte concentrations are given in mEq/l. ECF, extracellular fluid;
SID, strong ion difference.208
Table 5) are likely to cause a progressive metabolic alkalosis
from the outset. Again, evidence is limited, but in support of
this statement Plasma-Lyte 148 priming cardiopulmonary
bypass pumps has been shown to increase arterial base
excess by the end of bypass [25]. On the other hand, if there
is a pre-existing metabolic acidosis, caused by diabetic
ketoacidosis or hypovolaemic shock for example, then fluids
with higher effective SID such as Isolyte E or Plasma-Lyte
148 will correct the acidosis more rapidly (provided their
organic anions are metabolized with efficiency) while
counteracting ongoing generation of acidosis. The problem
with high SID fluids is the potential for over-correction and
‘break through’ metabolic alkalosis, particularly when the
cause of the acidosis is accumulation of organic strong
anions such as ketoacids and lactate, which disappear as the
illness resolves.
Unfortunately, available commercial ‘balanced’ preparations
have unresolved problems. Many contain either calcium or
magnesium (or sometimes both; Table 5). Calcium neutralizes
the anticoagulant effect of citrate, and both can precipitate in
the presence of HCO3
– and CO2
2–. This restricts their range
of ex vivo compatibilities (e.g. there are incompatibilities with
stored blood and sodium bicarbonate preparations) and
makes them poor drug delivery vehicles. Another
disadvantage is that they all require an intermediary metabolic
step, often at times of severe metabolic stress, to achieve
their effective SID.
Hartmann’s solution is also hypotonic relative to extracellular
fluid. Although a potential disadvantage in traumatic brain
injury [55], this was not borne out in a comparison with
hypertonic saline given prehospital to hypotensive brain-
injured patients [56]. Diabetic ketoacidosis is another
scenario that predisposes to brain swelling during fluid
loading [57], but here Hartmann’s solution and other mildly
hypotonic preparations seem safe for a least part of the
repletion process [58–61]. If used from the beginning, the
slightly alkalinizing Hartmann’s SID of 27 mEq/l is probably
sufficient to ameliorate or even prevent the late-appearing
normal anion gap metabolic acidosis to which these patients
are prone [57], although this remains to be demonstrated.
Overcoming current shortcomings
Given the limitations of commercially available solutions and
assuming that infusion-related acidosis causes harm, as
seems likely [62], then an argument could be put for new
‘balanced’ resuscitation solutions. Ideally, these should be
normotonic and free of organic anion surrogates and divalent
cations. The design could be along the lines of solution 3 in
Table 4. However, because solution 3 requires CO2-
impermeable storage, solution 2 might be preferable,
provided its higher pH does not preclude rapid peripheral
administration. Such a fluid could become the first line
crystalloid in all large volume infusion scenarios, including
intraoperative fluid replacement, acute normovolaemic
haemodilution and cardiopulmonary bypass, as well as
resuscitation of hypovolaemic and distributive shock, diabetic
ketoacidosis and hyperosmolar nonketotic coma. Refine-
ments would include a selection of [Na+] and corresponding
[Cl–] values to cater for varying osmolality requirements. The
standard SID for neutral acid–base effects would be
24 mEq/l, perhaps with variations above or below to correct
pre-existing acid–base disturbances.
Colloids
The SAFE (Saline versus Albumin Fluid Evaluation) study has
lifted the cloud hanging over albumin solutions [63], and
clinicians should now feel more comfortable using colloid
preparations in general. Just as with crystalloids, the
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Table 4
Four balanced crystalloids (see text)
Solution 1 Solution 2 Solution 3 Solution 4
[Na+] 140 140 140 140
[Cl–] 116 116 116 114
[HCO3
–] 19.2 24
[CO3
2–] 4.8
[OH–]2 4
[L-lactate] 26
PCO2 (mmHg) 0 0.3a 760 0.3a
pH 12.38 9.35 6.04 6.49
Effective SID 24 24 24 24
aAtmospheric sea level partial CO2 tension (PCO2). Electrolyte
concentrations are given in mEq/l. SID, strong ion difference.
Table 5
Four commercial crystalloids
Plasma-Lyte Isolyte  S 
Hartmann’s 148 (pH 7.4) Isolyte E
[Na+] 129 140 141 140
[Cl–] 109 98 98 103
[K+]5 5 5 1 0
[Ca2+]4 5
[Mg2+]3 3 3
[L-lactate] 29
[Acetate] 27 27 49
[Gluconate] 23 23
[Citrate] 8
[Phosphate] 1
Effective SID 27a 50 50 57
aAssumes stable plasma lactate concentrations of 2 mmol/l (see text).
All concentrations are given in mEq/l.209
effective SID of a colloid is a fundamental acid–base
property. This is tempered by two other factors. First, lower
infusion volumes are normally required for the same
haemodynamic effect [63], reducing the forcing function of
SID equilibration. Second, the colloid molecule itself may be
a weak acid. In other words some colloids contain ATOT, as is
the case with albumin and gelatin preparations (Table 6)
[64]. ATOT dilutional alkalosis is thus reduced or eliminated
when these fluids are infused, at least until the colloid
disappears from the extracellular space.
However, the SID values of commercially available weak acid
colloids are all significantly greater than zero (Table 6). On
infusion, the raised SID will tend to offset the acid–base
effects of ATOT infusion. As a result the overall tendency of
standard albumin and gelatin based colloids to cause
metabolic acidosis is probably similar to that of saline. By
contrast, hetastarch and pentastarch are not weak acids, and
the SID of standard starch preparations is zero (Table 6).
Their acid–base effects are therefore likely to be similar to
those of saline and the weak acid colloids [17].
‘Balanced’ colloids are still at the investigational stage.
Hextend (Table 6) is a balanced hetastarch preparation [65].
It contains L-lactate, which, by raising the effective SID to
26 mEq/l, reduces or eliminates infusion related metabolic
acidosis, and perhaps improves gastric mucosal blood flow
[66]. Experimentally, this appears to offer a survival
advantage in endotoxaemia [67].
Blood
At collection, blood is mixed with a preservative, normally
CPDA-1 [68], providing approximately 17 mEq trivalent
citrate anions per unit, and a small amount of phosphate [69].
The accompanying sodium cation adds about 40 mEq/l to the
effective SID of whole blood. For this reason it is not
surprising that large volume whole blood transfusion
commonly results in a post-transfusion metabolic alkalosis
(following citrate metabolism). With packed red cells, the
standard red cell preparation in most countries, the
preservative load per blood unit is reduced. Nevertheless,
large volume replacement with packed red cells still produces
metabolic alkalosis [69]. Conversely, if liver dysfunction is
severe enough to block or grossly retard citrate metabolism,
then the problem becomes ionized hypocalcaemia and
metabolic acidosis [70].
Conclusion
The principles laid down by the late Peter Stewart have
transformed our ability to understand and predict the
acid–base effects of fluids for infusion. As a result, designing
fluids for specific acid–base outcomes is now much more a
science than an art.
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Table 6
Six colloid solutions
Albumex 4 Haemaccel Gelofusine PENTASPAN HESpan Hextend
[Albumin]b 40 g/l
[Gelatin urea-linked]b 35 g/l
[Gelatin succinylated]b 40 g/l
[Pentastarch] 100 g/l
[Hetastarch] 60 g/l 60 g/l
[Na+] 140 145 154 154 154 143
[K+]5 . 1 3
[Ca2+] 12.5 5
[Mg2+] 0.8
[Cl–] 128 145 120 154 154 124
[L-lactate] 28
[Glucose] 5.5
[Octanoate] 6.4
Effective SID 12 17.6 34 0 0 26a
aAssumes stable plasma lactate concentrations of 2 mmol/L (see text). bWeak acid. Electrolyte concentrations are given in mEq/l. SID, strong ion
difference.210
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